Vaxalto Biotherapeutics And Mount Sinai Enter Into Exclusive License Agreement For The Development And Commercialization Of Novel Immunotherapeutic Oncolytic Viruses For Treatment Of Cancer

Press/Media

Period3 Mar 2021

Media coverage

14

Media coverage